- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556473
F-Tryptophan PET/CT in Human Cancers
A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Csaba Juhasz, M.D., Ph.D
- Phone Number: 313-966-5136
- Email: csaba.juhasz@wayne.edu
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Karmanos Cancer Institute
-
Contact:
- Csaba Juhasz, MD, PhD
- Phone Number: 313-966-5136
- Email: csaba.juhasz@wayne.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
- Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
- Women of childbearing potential must not be pregnant or breastfeeding.
- Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
- Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
- Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
Inclusion Criteria Specific for Intracranial Tumors
- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.
Inclusion Criteria Specific for Extracranial Neuroendocrine Tumors:
- Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
- ECOG performance status of 2 or better.
- Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release [LAR], depot) for >3 months before enrollment may be enrolled on the study, but such treatment is not required.
Inclusion Criteria specific for Extracranial Primary Breast tumors:
- Clinical and radiological diagnosis of a breast cancer
- ECOG performance status of 2 or better.
Inclusion Criteria specific for Rectal tumors:
- Histologically confirmed colorectal cancer, which is located in the rectum.
- ECOG performance status of 2 or better.
Exclusion Criteria:
- Patients who are pregnant or lactating are excluded.
Exclusion Criteria Specific for Intracranial Tumors:
- Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
- Tumor surgery or radiation within 1 month prior to the PET scan
Exclusion Criteria Specific for Extracranial Neuroendocrine Tumors:
- Tumor-directed therapy within 3 months to the area of planned imaging.
- Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).
- Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.
Exclusion Criteria for Extracranial Primary Breast tumors:
-Recent (within 1 month) tumor resection or radio-chemotherapy (acute/subacute post-treatment inflammatory changes may cause false positive increases on PET).
Exclusion Criteria for Rectal tumors:
-Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [18F]FETrp PET radiotracer
All participants will receive the tracer to evaluate the uptake of [18F]FETrp PET/CT on intra- and extracranial cancers.
|
Radioactive tracer 1-(2-[18F]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue)
Time Frame: During procedure (from right after tracer injection to 1-hour post-injection)
|
The percent difference in 1-(2-[18F]fluoroethyl)-L-tryptophan tracer standardized uptake values, measured between tumor and non-tumor (normal) tissues by PET/CT imaging, in each subject, will be calculated.
Mean and standard deviation of the percent differences will be calculated for each tumor type.
|
During procedure (from right after tracer injection to 1-hour post-injection)
|
Correlation between the 1-(2-[18F]fluoroethyl)-L-tryptophan tracer uptake values and the tracer transport rates measured in the same breast tumor tissue.
Time Frame: During procedure (from right after tracer injection to 1-hour post-injection)
|
The 1-(2-[18F]fluoroethyl)-L-tryptophan tracer standardized uptake values and the volume of distribution (characterizing the tracer transport rates) will be measured by PET/CT imaging in the same breast tumor tissues, and the correlation of these two measures will be calculated.
|
During procedure (from right after tracer injection to 1-hour post-injection)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiation doses to the various organs.
Time Frame: During procedure (from right after tracer injection to 1-hour post-injection)
|
Radiation doses received by the various organs (heart, lungs, pancreas, gallbladder, liver, small intestines, kidneys, muscle, bladder, ovaries/testes) will be measured from the dynamic 1-(2-[18F]fluoroethyl)-L-tryptophan PET/CT images.
Mean and standard deviation of the radiation doses will be calculated for each organ.
|
During procedure (from right after tracer injection to 1-hour post-injection)
|
Overall radiation dose to the study participants.
Time Frame: During procedure (from right after tracer injection to 1-hour post-injection)
|
Overall radiation dose received by the study participants from the PET/CT scan will be calculated from the dynamic 1-(2-[18F]fluoroethyl)-L-tryptophan PET/CT images.
Mean and standard deviation of the overall radiation dose will be calculated.
|
During procedure (from right after tracer injection to 1-hour post-injection)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Csaba Juhasz, M.D.,Ph.D, Barbara Ann Karmanos Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
Clinical Trials on 1-(2-[18F]FLUOROETHYL)-L-Tryptophan
-
University of Alabama at BirminghamNot yet recruitingHigh Grade GliomaUnited States
-
Charite University, Berlin, GermanyUnknown
-
University Hospital, ToulouseCompleted
-
Asan Medical CenterRecruitingPatients With Suspected or Diagnosed Central Nervous System LymphomaKorea, Republic of
-
Thomas HopeActive, not recruitingRecurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
University of Colorado, DenverCompletedPost-operative DeliriumUnited States
-
Fundacion Clinic per a la Recerca BiomédicaCompletedParkinson's Disease | Parkinson-Dementia SyndromeSpain
-
Fundacion Clinic per a la Recerca BiomédicaCompletedParkinsonism | Progressive Supranuclear Palsy | Multi-System AtrophySpain
-
University of PennsylvaniaActive, not recruitingBreast Cancer | Breast NeoplasmUnited States
-
Washington University School of MedicineCompletedPatients With Post Orthotopic Heart Transplantation StatusUnited States